Möchten Sie immer auf dem neuesten Stand bleiben?

Oslo, Norway, 7 May 2014: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for the first...

Please find enclosed an invitation to the annual general meeting at Photocure ASA on 27 May 2014 at 17:00 hours (CET). The meeting will take place at Photocure's head office at Hoffsveien 4, 2nd...

Photocure will present its first quarter report on Wednesday 7 May 2014 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives from the company will be...

The Annual report 2013 for Photocure ASA is enclosed in English and Norwegian. The Annual report is also available on the company's website http://www.photocure.com/Investor-relations/. For further...

Oslo, Norway, 27 February 2014: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for the...

Photocure will present its fourth quarter and full year report 2013 on Thursday 27 February 2014 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives...

Oslo, Norway, December 27, 2013: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces an update on Cevira, which is...

Oslo, Norway, 19 December 2014 Photocure ASA presents its financial calendar for 2014: 27 February 2014 - Presentation of the fourth quarter and full year 2013 7 May 2014 - Presentation of the...

Oslo, Norway, November 28, 2013: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces that the US Centers for...

  This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. ...